文献速递前列腺癌

低危前列腺癌比较效果研究中治疗选择偏倚对生存的影响量化

Quantifying treatment selection bias effect on survival in comparative effectiveness research: findings from low-risk prostate cancer patients.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2020-09-28

基于SEER数据库2005-2015年50,804例低危前列腺癌患者,比较根治性前列腺切除术、近距离放疗和外照射放疗的10年总生存差异。全队列10年前列腺癌特异性生存达99%,但总生存分别为92.9%、83.6%和76.9%,倾向评分匹配后差异仍存在,治疗选择偏倚效应估计为6.5%至15.0%。

要点

  • 低危前列腺癌10年前列腺癌特异性生存约99%,治疗方式间无差异。
  • 根治术10年总生存92.9%,显著高于近距离放疗83.6%和外照射76.9%。
  • 治疗选择偏倚对总生存的效应量为6.5%至15.0%,需在注册数据库比较效果研究中考虑。

核心结论

  • 低危前列腺癌患者中,选择根治术者与放疗相比总生存差异大,但前列腺癌特异性生存相似,提示总生存差异几乎完全由治疗选择偏倚驱动。

研究设计与样本

  • 回顾性队列研究,查询SEER数据库2005-2015年低危前列腺癌(cT1-T2a、PSA<10、Gleason 6)接受根治术、近距离放疗或外照射放疗的患者,共50,804例(根治术8,845例;近距离放疗18,252例;外照射23,707例),中位随访7.4年。
  • 采用倾向评分匹配估计由已测量混杂因素和未测量混杂因素导致的治疗选择偏倚效应。

主要发现

  • 全队列10年前列腺癌特异性生存为99%。
  • 10年总生存:根治术92.9%,近距离放疗83.6%,外照射76.9%(p<0.001)。
  • 倾向评分匹配后总生存差异仍持续:根治术 vs 外照射7.4%,根治术 vs 近距离放疗4.6%,近距离放疗 vs 外照射3.7%(均p<0.001)。
  • 治疗选择偏倚对10年总生存的估计效应:根治术 vs 外照射15.0%(已测量8.6%,未测量6.4%),根治术 vs 近距离放疗8.5%(已测量4.8%,未测量3.7%),近距离放疗 vs 外照射6.5%(已测量3.1%,未测量3.4%)。

临床怎么用

  • 解读基于国家注册数据库的前列腺癌比较效果研究时,应充分考虑治疗选择偏倚对总生存的量化影响,避免将总生存差异直接归因于治疗效应。
  • 低危前列腺癌治疗决策应以前列腺癌特异性生存为主要肿瘤学终点,总生存差异需谨慎解释。

局限性

  • 为回顾性研究,存在未测量混杂因素,治疗选择偏倚效应通过模型估计而非随机化验证。
  • 仅纳入低危前列腺癌患者,结论外推至其他风险组需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Comparative effectiveness research (CER) using national registries influences cancer clinical trial design, treatment guidelines, and patient management. However, the extent to which treatment selection bias (TSB) affects overall survival (OS) in cancer CER remains poorly defined. We sought to quantify the TSB effect on OS in the setting of low-risk prostate cancer, where 10-year prostate cancer-specific survival (PCSS) approaches 100% regardless of treatment modality. METHODS: The Surveillance, Epidemiology, and End Results database was queried for patients with low-risk prostate cancer (cT1-T2a, PSA < 10, and Gleason 6) who received radical prostatectomy (RP), brachytherapy (BT), or external beam radiotherapy (EBRT) from 2005 to 2015. The TSB effect was defined as the unadjusted 10-year OS difference between modalities that was not due to differences in PCSS. Propensity score matching was used to estimate the TSB effect on OS due to measured confounders (variables present in the database and associated with OS) and unmeasured confounders. RESULTS: A total of 50,804 patients were included (8845 RP; 18,252 BT; 23,707 EBRT) with a median follow-up of 7.4 years. The 10-year PCSS for the entire cohort was 99%. The 10-year OS was 92.9% for RP, 83.6% for BT, and 76.9% for EBRT (p < 0.001). OS differences persisted after propensity score matching of RP vs. EBRT (7.4%), RP vs. BT (4.6%), and BT vs. EBRT (3.7%) (all p < 0.001). The TSB effect on 10-year OS was estimated to be 15.0% for RP vs. EBRT (8.6% measured, 6.4% unmeasured), 8.5% for RP vs. BT (4.8% measured, 3.7% unmeasured), and 6.5% for BT vs. EBRT (3.1% measured, 3.4% unmeasured). CONCLUSIONS: Patients with low-risk prostate cancer selected for RP exhibited large OS differences despite similar PCSS compared to radiotherapy, suggesting OS differences are almost entirely driven by TSB. The quantities of these effects are important to consider when interpreting prostate cancer CER using national registries.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Miccio JA, Talcott WJ, Jairam V, et al. Quantifying treatment selection bias effect on survival in comparative effectiveness research: findings from low-risk prostate cancer patients. Prostate Cancer Prostatic Dis. 2020. PMID: 32989262. doi:10.1038/s41391-020-00291-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。